Table 1.

Abbreviated list of digital endpoints [30]

Study phase 4	Indication Sickle cell anemia	Endpoint Change in total physical activity from baseline to weeks 10–12 and 22–24	Technology Activity monitor	Measurement Activity count
4	Sickle cell anemia	Change in mean nocturnal hemoglobin oxygen saturation percentage from baseline, week 10–12, and week 22–24	Pulse oximeter	Overnight pulse oximetry
1	Menopause, depression, and anxiety	Change in wake after sleep onset from beginning of study to weeks 4, 8, 12, and 16	Activity monitor	Wake time after sleep onset
3	Parkinson's disease	Change in PD symptoms as assessed by the Parkinson's KinetiGraph/personal KinetiGraph wearable device from baseline to week 12	Activity monitor	Tremor, bradykinesia, dyskinesia, and daytime somnolence
4	Diabetes mellitus	Percent time in euglycemia by a continuous glucose monitor during the final 14 days of each treatment	Continuous glucose monitor	Glycemic variability
2	Diabetic foot ulcer	Change in physiologic stress response	Heart rate monitor	Heart rate variability
2	Alzheimer's disease	Change in speech features from baseline to week 48	Microphone (audio recordings)	Acoustic and linguistic language features
2	COPD	Average change in pre-bronchodilator FEV1 from week 16 to week 24	Home spirometer	FEV1
3	Chronic cough	Percentage of participants with a ≥30% reduction from baseline in 24-h coughs per hour at week 24	Chest contact sensor with audio recording	Cough count
4	Asthma	Percentage of rescue-free days between month 4 and month 6 as determined by the rescue medication sensor	Ingestible sensor	Medication adherence

These examples were selected to demonstrate the broad set of contexts in which digital endpoints are employed and for their relatively recent initiation dates (between December 2017 and August 2020) [30].